LIQUID CHROMATOGRAPHY DEPENDENT STABILITY INDICATING METHODOLOGY: DEVELOPMENT AND AUTHENTICATION FOR FORMULATIONS OF CAPSULE TYPE CONTAINING TEGAFUR, GIMERACIL, AND OTERACIL

MAILAMURI HARITHA KUMARI; BALA MURALI KRISHNA KHANDAPU; RUDRARAJU RAMESH RAJU

doi:10.22159/ijap.2023v15i4.47831

Authors

MAILAMURI HARITHA KUMARI Department of chemistry, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh, India https://orcid.org/0009-0006-9752-2121
BALA MURALI KRISHNA KHANDAPU Department of chemistry, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh, India
RUDRARAJU RAMESH RAJU Department of chemistry, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh, India

DOI:

https://doi.org/10.22159/ijap.2023v15i4.47831

Keywords:

Tegafur, Tegonate capsule, Gimeracil, HPLC, Oteracl, Stability

Abstract

Objective: This investigation entitles the development and authentication of a rapid, selective and explicit RP-HPLC technique to assay tegafur (TGR), gimeracil (GMR), and oteracil (OTR) simultaneously in bulk and formulations of capsule type.

Methods: The separation, detection and assessment of TGR, GMR and OTR were achieved using a C18 Agilent Zorbax (25 cm; 4.6 mm; 5 µm particle dimension) reverse phase column. The acetonitrile (40% by volume) and 0.1% triethylamine in distilled water (pH 2.5, 60% by volume) was utilized as mobile phase. The validation of the method and degradation study was performed as per the strategy given by ICH.

Results: The retention periods in Agilent Zorbax column for OTR, TGR, and GMR were 2.458 min, 7.236 min and 8.629 min, respectively. Linearity was seen in the concentration series of 5.0-30.0 µg/ml (TGR), 1.45-8.70 µg/ml (GMR), and 3.95-23.70 µg/ml (OTR). The regression coefficient was greater than 0.999. The LOQ values were 0.606 µg/ml (TGR), 0.175 µg/ml (GMR), and 0.478 µg/ml (OTR). The percent comparative standard deviation (exactness) values were bestowed to be 0.243%-0.676%, 0.293%-1.894% and 0.269%-0.615% for TGR, GMR and OTR, respectively. The percent recoveries (accuracy) were in the range of 100.044%-100.493 for TGR, 99.730%-100.335% for GMR and 100.064%-100.543% for OTR.

Conclusion: The research results of the degradation investigation proved the technique's specificity as well as stability indicating feature. The process could be used for routine evaluation of OTR, TGR, and GMR in formulations of capsule type.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660, PMID 33538338.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107, PMID 21296855.

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-48. doi: 10.2147/CMAR.S149619. PMID 29445300.

Yen HH, Chen CN, Yeh CC, Lai IR. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience. World J Surg Oncol. 2021;19(1):124. doi: 10.1186/s12957-021-02233-2, PMID 33865416.

Mahlberg R, Lorenzen S, Thuss Patience P, Heinemann V, Pfeiffer P, Mohler M. New perspectives in the treatment of advanced gastric cancer: S-1 as a novel oral 5-FU therapy in combination with cisplatin. Chemotherapy. 2017;62(1):62-70. doi: 10.1159/000443984, PMID 27643822.

Matt P, Van Zwieten Boot B, Calvo Rojas G, Ter Hofstede H, Garcia Carbonero R, Camarero J. The European medicines agency review of tegafur/gimeracil/oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the scientific assessment of the committee for medicinal products for human use (CHMP). Oncologist. 2011;16(10):1451-7. doi: 10.1634/theoncologist.2011-0224, PMID 21963999.

Liu H, Wang Y, Li G, Song W, Wang R. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer. J Cancer Res Ther. 2015;11(2):331-5. doi: 10.4103/0973-1482.157339, PMID 26148595.

Chen J, Wang J, Xu T. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: a systematic review and meta-analysis. Medicine. 2019;98(30):e16667. doi: 10.1097/MD.0000000000016667, PMID 31348323.

Ahmed S, Islam MS, Ullah B, Kanti Biswas S, Samad Azad MA, Hossain MS. A review article on pharmaceutical analysis of pharmaceutical industry according to pharmacopoeias. Orient J Chem. 2020;36(1):1-10. doi: 10.13005/ojc/360101.

Zacharis CK, Markopoulou CK. Recent trends in pharmaceutical analytical chemistry. Molecules. 2020;25(16):3560. doi: 10.3390/molecules25163560, PMID 32764423.

Nikolin B, Imamovic B, Medanhodzic Vuk S, Sober M. High performance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004;4(2):5-9. doi: 10.17305/bjbms.2004.3405, PMID 15629016.

Martins YA, Gonçalves TM, Lopez RFV. HPLC methods for choloroquine determination in biological samples and pharmaceutical products. Daru. 2021;29(1):223-39. doi: 10.1007/s40199-021-00391-y, PMID 33738722.

Fares MY, Hegazy MA, El-Sayed GM, Abdelrahman MM, Abdelwahab NS. Quality by design approach for green HPLC method development for simultaneous analysis of two thalassemia drugs in biological fluid with pharmacokinetic study. RSC Adv. 2022;12(22):13896-916. doi: 10.1039/d2ra00966h, PMID 35548387.

Kowalska M, Wozniak M, Kijek M, Mitrosz P, Szakiel J, Turek P. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. Sci Rep. 2022;12(1):1. doi: 10.1038/s41598-021-99269-x, PMID 34992227.

Yadav PK, Tiwari AK, Saklani R, Chauhan D, Rana R, Yadav P. HPLC method for simultaneous estimation of paclitaxel and baicalein: pharmaceutical and pharmacokinetic applications. Bioanalysis. 2022;14(14):1005-20. doi: 10.4155/bio-2022-0100, PMID 36066029.

Mallavarapu R, Katari NK, Dongala T, Rekulapally VK, Marisetti VM, Vyas G. A validated stability-indicating reversed-phase-HPLC method for dipyridamole in the presence of degradation products and its process-related impurities in pharmaceutical dosage forms. Biomed Chromatogr. 2022;36(1):e5247. doi: 10.1002/bmc.5247, PMID 34541698.

Naresh P, Kumar KV. Leflunomide tablet formulation: development and validation of an RP-HPLC technique. Int J Pharm Pharm Sci. 2023;15(1):16-21. doi: 10.22159/ijpps.2023v15i1.46505.

Attia KA, Madkour AW, Almrasy AA, Abdelfatah AM. Determination of toltrazuril in the presence of complete alkaline degradation product by RP-HPLC and TLC-densitometric methods. Int J Pharm Pharm Sci. 2022;14(5):49-56. doi: 10.22159/ijpps.2022v14i5.44179.

Chandar PB, Madhuri MS, Hyma KN, Anusha S, Rasool SN. ARP-HPLC stability indicating method development and validation for the simultaneous determination of netupitant and palonosetron in pharmaceutical dosage form. Int J Curr Pharm Sci. 2022;14(4):60-7. doi: 10.22159/ijcpr.2022v14i4.1985.

Katolkar P, Jaiswal S. Analytical method development and validation for the estimation of cyamemazine tartrate in formulation by RP-HPLC with stability indicating. Asian J Pharm Clin Res. 2022;15(9):28-32. doi: 10.22159/ajpcr.2022.v15i9.45154.

Ramoller IK, Abbate MTA, Vora LK, Hutton ARJ, Peng K, Volpe Zanutto F. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues. J Pharm Biomed Anal. 2022;213:114698. doi: 10.1016/j.jpba.2022.114698. PMID 35259714.

Shiraiwa K, Suzuki Y, Uchida H, Iwashita Y, Tanaka R, Iwao M. Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/lV combination therapy after hepatectomy. Sci Rep. 2021;11(1):3132. doi: 10.1038/s41598-021-82908-8, PMID 33542452.

Peer CJ, McManus TJ, Hurwitz HI, Petros WP. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. J Chromatogr B Anal Technol Biomed Life Sci. 2012;898:32-7. doi: 10.1016/j.jchromb.2012.04.010, PMID 22565063.

Broto M, McCabe R, Galve R, Marco MP. A high throughput immunoassay for the therapeutic drug monitoring of tegafur. Analyst. 2017;142(13):2404-10. doi: 10.1039/c7an00418d. PMID 28555688.

Liu K, Zhong D, Zou H, Chen X. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010;52(4):550-6. doi: 10.1016/j.jpba.2010.01.026. PMID 20138454.

International conference on harmonization. ICH stability testing of new drug substances and products. Vol. Q1A(R2); 2003.

International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2 (R1); 2005.

Sharma S, Goyal S, Chauhan K. A review on analytical method development and validation. Int J App Pharm. 2018;10(6):8-15. doi: 10.22159/ijap.2018v10i6.28279.

Snyder LR, Dolan JW. Optimizing selectivity during reversed-phase high-performance liquid chromatography method development: prioritizing experimental conditions. J Chromatogr A. 2013;1302:45-54. doi: 10.1016/j.chroma.2013.05.082, PMID 23830242.

Sabir AM, Moloy M, Bhasin PS. HPLC method development and validation: a review. Int Res J Pharm. 2015;4(4):39-46. doi: 10.7897/2230-8407.04407.

Ismail R, Lee HY, Mahyudin NA, Abu Bakar F. Linearity study on detection and quantification limits for the determination of avermectins using linear regression. J Food Drug Anal. 2014;22(4):407-12. doi: 10.1016/j.jfda.2014.01.026. PMID 28911453.

Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29Suppl 1:S49-52. PMID 18852857.

Ira SK, Michael ES. Analytical method validation: back to basics, Part II. LCGC North Am. 2011;29(1):44-52.

Suresh R, Anarthanan S, Manavalan R, Valliappan K. Aspects of validation in HPLC method development for pharmaceutical analysis-comparison of validation requirements by FDA, USA and ICH. Int J Pharm Sci Res. 2010;12:123-33.

Rochani AK, Wheatley M, Oeffinger BE, Eisenbrey JR, Kaushal G. LC-MS based stability-indicating method for studying the degradation of lonidamine under physical and chemical stress conditions. Res Pharm Sci. 2020;15(4):312-22. doi: 10.4103/1735-5362.293509, PMID 33312209.

Henry TR, Penn LD, Conerty JR, Wright FE, Gorman G, Pack BW. Best practices in stability indicating method development and validation for non-clinical dose formulations. AAPS J. 2016;18(6):1418-23. doi: 10.1208/s12248-016-9976-0, PMID 27600135.